SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

ANIP

ANI Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The massive EPS beat and raised guidance signal accelerating Rare Disease momentum and operational leverage. The $100M buyback adds a capital return catalyst. Watch for continued Cortrophin Gel adoption in acute gouty arthritis and the Phase 4 SYNCHRONICITY trial readout in H2 2026 as next catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$81.86
T+0 close · May 8, 2026 · via day close
Latest settled
−3.25%
T+60 · $79.20
Vs SPY
−8.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $81.86entry
  2. T+1 · 7mo ago −3.85%α −4.08% · $78.71
  3. T+5 · 6mo ago −2.79%α −4.25% · $79.58
  4. T+20 · 6mo ago −0.92%α −0.94% · $81.11
  5. T+60 · 4mo ago −3.25%α −8.09% · $79.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 consensus by 57.7%, on revenue of $237.5M (20.5% YoY growth), above the $207.6M consensus. The company raised full-year 2026 guidance for revenue to $1.08B-$1.14B and adjusted EPS to $9.19-$9.69, and authorized a $100M share repurchase program. Cortrophin Gel revenue grew 42.1% YoY to $75.1M, and the Rare Disease segment expanded 36.9%.

Key Financial Metrics

EPS
$2.05
est $1.30 · +57.7%
Revenue
$237.5M
est $207.6M · +14.4% · +20.5% YoY
Rating
strong beat
Guidance
$1,080 million to $1,140 million
raised
Gross Margin
60.6%

Key Facts

  • Q1 2026 adjusted non-GAAP diluted EPS of $2.05 vs consensus $1.30 (57.7% beat)
  • Q1 2026 total net revenue of $237.5M vs consensus $207.6M (14.4% beat), up 20.5% YoY
  • Cortrophin Gel net revenue of $75.1M, up 42.1% YoY
  • Raised FY2026 guidance: revenue $1.08B-$1.14B (prev. $1.055B-$1.115B), adjusted EPS $9.19-$9.69 (prev. $8.83-$9.34)
  • Board authorized $100M share repurchase program through May 2029
  • GAAP net income available to common shareholders of $29.5M ($1.28 diluted EPS) vs $15.3M ($0.69) in prior year
  • Adjusted non-GAAP EBITDA of $63.0M, up 24.1% YoY
  • Cash flow from operations of $58.4M in Q1; $311.2M unrestricted cash at quarter end

Financial Impact

Q1 revenue beat consensus by ~$29.9M (14.4%); EPS beat by $0.75 (57.7%); FY guidance raised by $25M at midpoint for revenue and $0.36 for adjusted EPS

revenueepsebitdaguidanceshare repurchase

Risk Factors

  • Brands revenue declined 50.9% YoY, indicating normalization in demand for certain products
  • Gross margin contracted ~230bps YoY (GAAP) due to higher royalty-bearing product mix
  • Dependence on Cortrophin Gel for growth; insurance re-verification seasonality could impact future quarters
  • Debt of $625M principal outstanding; interest expense remains a cash flow drag

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290972

Track record

34 reports on ANIP

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026